## Sonia Alonso-Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3953567/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	FoxO maintains a genuine muscle stem-cell quiescent state until geriatric age. Nature Cell Biology, 2020, 22, 1307-1318.	10.3	96
2	Pericytes in the myovascular niche promote post-natal myofiber growth and satellite cell quiescence. Development (Cambridge), 2015, 142, 1242-53.	2.5	83
3	Gene Expression Profiling of Muscle Stem Cells Identifies Novel Regulators of Postnatal Myogenesis. Frontiers in Cell and Developmental Biology, 2016, 4, 58.	3.7	63
4	Expression of podocalyxin enhances the adherence, migration, and intercellular communication of cells. Experimental Cell Research, 2008, 314, 2004-2015.	2.6	43
5	Role of transcription factor Sp1 and CpG methylation on the regulation of the human podocalyxin gene promoter. BMC Molecular Biology, 2006, 7, 17.	3.0	41
6	Cellular localization of the cell cycle inhibitor Cdkn1c controls growth arrest of adult skeletal muscle stem cells. ELife, 2018, 7, .	6.0	36
7	BMP signaling regulates satellite cell dependent postnatal muscle growth. Development (Cambridge), 2017, 144, 2737-2747.	2.5	34
8	Synemin acts as a regulator of signalling molecules in skeletal muscle hypertrophy. Journal of Cell Science, 2014, 127, 4589-601.	2.0	31
9	Identification and Characterization of the Dermal Panniculus Carnosus Muscle Stem Cells. Stem Cell Reports, 2016, 7, 411-424.	4.8	30
10	Podocalyxin enhances the adherence of cells to platelets. Cellular and Molecular Life Sciences, 2007, 64, 2965-2974.	5.4	21
11	The Skeletal Muscle Emerges as a New Disease Target in Amyotrophic Lateral Sclerosis. Journal of Personalized Medicine, 2021, 11, 671.	2.5	20
12	Ventricular enlargement associated with the panneural ablation of the podocalyxin gene. Molecular and Cellular Neurosciences, 2010, 43, 90-97.	2.2	18
13	Association of Rex-1 to target genes supports its interaction with Polycomb function. Stem Cell Research, 2011, 7, 1-16.	0.7	18
14	SOXF factors regulate murine satellite cell self-renewal and function through inhibition of β-catenin activity. ELife, 2018, 7, .	6.0	17
15	Functional Analysis of <i>Rex1</i> During Preimplantation Development. Stem Cells and Development, 2013, 22, 459-472.	2.1	16
16	Disruption of the Cys5-Cys7 disulfide bridge in the platelet glycoprotein Ibβ prevents the normal maturation and surface exposure of GPIb-IX complexes. Thrombosis and Haemostasis, 2003, 90, 456-464.	3.4	13
17	A variant thrombasthenic phenotype associated with compound heterozygosity of integrin β3-subunit: (Met124Val)β3 alters the subunit dimerization rendering a decreased number of constitutive active αIIbβ3 receptors. Thrombosis and Haemostasis, 2004, 92, 1377-1386.	3.4	11
18	Production and characterization of murine monoclonal antibodies against human podocalyxin. Tissue Antigens, 2006, 68, 407-417.	1.0	9

#	Article	IF	CITATIONS
19	Megakaryocyte gene targeting mediated by restricted expression of recombinase Cre. Thrombosis and Haemostasis, 2011, 105, 138-144.	3.4	7
20	Overexpression of podocalyxin in megakaryocytes and platelets decreases the bleeding time and enhances the agonist-induced aggregation of platelets. Thrombosis Research, 2010, 125, e300-e305.	1.7	6
21	Phosphotyrosine phosphatase inhibitor bisperoxovanadium endows myogenic cells with enhanced muscle stem cell functions <i>via</i> epigenetic modulation of Scaâ€1 and Pw1 promoters. FASEB Journal, 2016, 30, 1404-1415.	0.5	6
22	Diminished Thrombogenic Responses by Deletion of the Podocalyxin Gene in Mouse Megakaryocytes. PLoS ONE, 2011, 6, e26025.	2.5	6
23	α-Adrenergic-mediated activation of human reconstituted fibrinogen receptor (integrin αIIbβ3) in Chinese hamster ovary cells. Thrombosis and Haemostasis, 2004, 92, 1368-1376.	3.4	5
24	A <i>p57</i> conditional mutant allele that allows tracking of <i>p57</i> â€expressing cells. Genesis, 2017, 55, e23025.	1.6	5
25	P3.25 Satellite cell dependent growth and regeneration of skeletal muscle requires BMP signalling. Neuromuscular Disorders, 2010, 20, 648.	0.6	0
26	G.O.20. Neuromuscular Disorders, 2014, 24, 921.	0.6	0
27	G.P.199. Neuromuscular Disorders, 2014, 24, 876.	0.6	0
28	G.P.195. Neuromuscular Disorders, 2014, 24, 875.	0.6	0